N/A
N=20
Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease
Peripheral Arterial Disease
Bottom Line
View on ClinicalTrials.gov: NCT02371785 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Mar 2019
Primary outcome: Primary: Device Technical Success — 29 lesions
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- CorPath 200 System (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Corindus Inc.
- Primary completion
- Apr 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Device Technical Success |
29 | — |
| PRIMARY Adverse Events |
— | — |
| SECONDARY Clinical Procedural Success |
20 | — |
| SECONDARY Fluoroscopy Time |
6.8 | — |
| SECONDARY Contrast Volume |
73.3 | — |
| SECONDARY Total Procedure Time |
45.5 | — |
| SECONDARY Interventional Procedure Time |
23.4 | — |
Summary
This study evaluates the performance of the CorPath 200 System to deliver guide wires and balloons to blockages in the arteries of the leg.
Eligibility Criteria
Inclusion Criteria
- General Inclusion
- At least 18 years of age;
- Symptomatic disease: presence of critical limb ischemia (including tissue loss or rest pain), or lifestyle-limiting claudication requiring intervention in iliac and/or superficial femoral arteries;
- The subject or the legally authorized representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent.
- Angiographic Inclusion
Presence of superficial femoral artery and/or iliac stenosis (>50%) or occlusion of up to 50 mm in length as determined by angiogram prior to index interventional procedure.
Exclusion Criteria
- General Exclusion
- Failure/inability/unwillingness to provide informed consent;
- Target vessel has been previously treated with bypass;
- Has an abdominal aortic aneurysm contiguous with the iliac artery target lesion;
- Has contraindication to anticoagulation;
- Has bleeding or a hypercoagulability disorder;
- Thrombocytopenia;
- Elevated international normalized ratio (>1.5);
- Elevated serum creatinine (≥2.5 mg/dL);
- Active infection;
- Contraindication to contrast; or
- Enrolled in concurrent clinical study.
- Angiographic Exclusion
- Target vessel:
- shows evidence of previous dissection or perforation, or
- has adjacent acute thrombus;
- Lesion is highly calcified;
- Lesion requires use of any atherectomy device during the procedure;
- Has a pre-existing target artery aneurysm or perforation or dissection of the target artery prior to initiation of the interventional procedure.
Data sourced from ClinicalTrials.gov (NCT02371785). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.